Ad
related to: best treatment for waldenstrom's macroglobulinemiadiscoverrocket.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Waldenström macroglobulinemia (/ ˈ v æ l d ən s t r ɒ m ˌ m æ k r oʊ ˌ ɡ l ɒ b j ə l ɪ ˈ n iː m i ə / VAL-dən-strom MAK-roh-GLOB-yə-lin-EE-mee-ə, [1] [2] US also / ˈ v ɑː l d ən s t r ɛ m-/ VAHL-dən-strem - [3]) is a type of cancer affecting two types of B cells: lymphoplasmacytoid cells and plasma cells.
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL).
Bing–Neel syndrome (BNS) is an extremely rare neurologic complication of Waldenström macroglobulinemia (WM), which is a chronic lymphoproliferative disorder. [1] There's no clear definition of BNS but what is known so far is that unlike WM, It involves the central nervous system (CNS), infiltrated by differentiated malignant B cells and by having hyperglobulinemia. [2]
The incidence of Waldenstrom’s macroglobulinemia ranges from 0.36 1, 2 to 0.57 3 per 100,000 people in the United States or approximately 1,200 to 1,900 annually. With a median disease duration approaching 10 years, 4 approximately 12,000 to 19,000 patients are living with Waldenstrom’s macroglobulinemia in the United States.
NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial. Responses are durable and deepen over time with two patients on treatment for greater than one year
It was approved by the US Food and Drug Administration (FDA) in November 2013, for the treatment of mantle cell lymphoma. [10] In February 2014, the FDA expanded the approved use of ibrutinib to chronic lymphocytic leukemia (CLL). [25] [26] It was approved for Waldenström's macroglobulinemia in 2015. [11] [27]
Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is a plasma cell dyscrasia, resembling leukemia, with cells of lymphocytic, plasmacytic, or intermediate morphology, which secrete a monoclonal immunoglobulin M component. There is diffuse infiltration by the malignant cells of the bone marrow ...
Usually, treatment continues until the patient has reached their target height, or they have stopped growing, she explains. However, there are certain cases where GH therapy could be lifelong.
Ad
related to: best treatment for waldenstrom's macroglobulinemiadiscoverrocket.com has been visited by 10K+ users in the past month